Grazax misses Phase III asthma prevention endpoint

ALK-Abello A/S (CSE:ALK-B) said Grazax/ Grastek ( MK-7243) missed the primary endpoint of time to first diagnosis of reversible impairment of lung function vs. placebo in the Phase III GAP trial, which evaluated whether Grazax could reduce children's risk of developing asthma. The double-blind European trial enrolled 812 children with allergic rhinoconjunctivitis and comprised a three-year treatment period and a two-year follow-up period.

The company said Grazax had a positive effect on children's asthma symptoms and use of asthma medication, an effect that was sustained in the two years after treatment. ...